Amarin | AMRN - Ebit

Aktienkurs
14.40
Täglich Wechseln
-0.15 -1.00%
Monatlich
2.16%
Jährlich
36.11%
Q1 Prognose
13.38




Ebit Veränderung Datum
AbbVie USD 5.81B 4.36B 2025-12
Alnylam Pharmaceuticals USD 29.4M 59.36M 2025-12
Amarin USD -1.7M 8.47M 2025-09
AstraZeneca USD 2.97B 4.48B 2025-12
BioCryst Pharmaceuticals USD -4.51M 12.2M 2024-12
DBV Technologies USD -34.28M 6.83M 2025-09
Esperion Therapeutics USD -16.03M 11.51M 2024-09
GlaxoSmithKline GBP 1.44B 1.35B 2025-12
Halozyme Therapeutics USD -88.41M 306.33M 2025-12
Heron Therapeutics USD -4.46M 5.76M 2024-09
Ionis Pharmaceuticals USD -215M 54.82M 2025-12
Nektar Therapeutics USD -34.34M 3.68M 2024-09
Neurocrine Biosciences USD 227.9M 11.4M 2025-12
Novartis USD -9.19B 13.87B 2025-06